Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc (NQ: VOR )

5.270 +0.300 (+6.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,328
Open 4.970
Bid (Size) 5.000 (5)
Ask (Size) 5.610 (1)
Prev. Close 4.970
Today's Range 4.960 - 5.350
52wk Range 3.480 - 9.720
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
From Vor Biopharma
Via Globe NewsWire
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Vor Biopharma
Via Globe NewsWire

Performance

YTD
-22.04%
-22.04%
1 Month
-22.04%
-22.04%
3 Month
+12.37%
+12.37%
6 Month
+10.48%
+10.48%
1 Year
-36.12%
-36.12%

More News

Read More
Analyzing Vor Biopharma's Short Interest
Via Benzinga
Dow Edges Higher; Prometheus Biosciences Shares Jump
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Drops 75 Points; Crude Oil Down 2%
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
From Vor Biopharma
Via Globe NewsWire
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
From Vor Biopharma
Via Globe NewsWire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via Globe NewsWire
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
From Vor Biopharma
Via Globe NewsWire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via Globe NewsWire
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
From Vor Biopharma
Via Globe NewsWire
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
From Vor Biopharma
Via Globe NewsWire
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
From Vor Biopharma
Via Globe NewsWire
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
3 Biotech Stock Picks From This Wedbush Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
79 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.